Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/157905Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Gonçalves, J | |
| dc.creator | Santos, CD | |
| dc.creator | Fresco, P | |
| dc.creator | Fernandez-Llimos, F | |
| dc.date.accessioned | 2024-08-11T23:07:04Z | - |
| dc.date.available | 2024-08-11T23:07:04Z | - |
| dc.date.issued | 2024 | |
| dc.identifier.issn | 0870-2551 | |
| dc.identifier.other | sigarra:666087 | |
| dc.identifier.uri | https://hdl.handle.net/10216/157905 | - |
| dc.description.abstract | [No abstract available] | |
| dc.language.iso | eng | |
| dc.rights | openAccess | |
| dc.title | Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one | |
| dc.type | Outra Publicação em Revista Científica Internacional | |
| dc.contributor.uporto | Faculdade de Farmácia | |
| dc.identifier.doi | 10.1016/j.repc.2023.10.005 | |
| dc.identifier.authenticus | P-00Z-V69 | |
| Appears in Collections: | FFUP - Outra Publicação em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 666087.pdf | 271.09 kB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
